Although these data suggest a role for IL-1β in both EAE and MS and provide a rationale for clinical trials that target the IL-1 axis [8], there are discordant results relating to the expression of IL-1β during the course of both diseases. The gene discussed is IL1B; the disease is myeloid sarcoma.